Literature DB >> 17384924

Comment on: Nauck MA, Duran S, Kim D et al (2007) A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 50:259-267.

P D Home.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17384924     DOI： 10.1007/s00125-007-0653-9

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  8 in total

1.  Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).

Authors:  A J Garber; J Wahlen; T Wahl; P Bressler; R Braceras; E Allen; R Jain
Journal:  Diabetes Obes Metab       Date:  2006-01       Impact factor: 6.577

2.  A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.

Authors:  Kjeld Hermansen; Melanie Davies; Taudeusz Derezinski; Gabrielle Martinez Ravn; Per Clauson; Philip Home
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

3.  Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study.

Authors:  H Yki-Järvinen; R Kauppinen-Mäkelin; M Tiikkainen; M Vähätalo; H Virtamo; K Nikkilä; T Tulokas; S Hulme; K Hardy; S McNulty; J Hänninen; H Levänen; S Lahdenperä; R Lehtonen; L Ryysy
Journal:  Diabetologia       Date:  2006-02-03       Impact factor: 10.122

4.  Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.

Authors:  Philip Raskin; Elsie Allen; Priscilla Hollander; Andrew Lewin; Robert A Gabbay; Peter Hu; Bruce Bode; Alan Garber
Journal:  Diabetes Care       Date:  2005-02       Impact factor: 19.112

5.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors:  Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

6.  A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study.

Authors:  M A Nauck; S Duran; D Kim; D Johns; J Northrup; A Festa; R Brodows; M Trautmann
Journal:  Diabetologia       Date:  2006-12-08       Impact factor: 10.122

7.  Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Authors:  Robert J Heine; Luc F Van Gaal; Don Johns; Michael J Mihm; Mario H Widel; Robert G Brodows
Journal:  Ann Intern Med       Date:  2005-10-18       Impact factor: 25.391

8.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112
  8 in total
  6 in total

Review 1.  Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes.

Authors:  Richard E Pratley
Journal:  Medscape J Med       Date:  2008-07-28

2.  Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors.

Authors:  Richard E Pratley; Matthew Gilbert
Journal:  Rev Diabet Stud       Date:  2008-08-10

Review 3.  Ten years of experience with biphasic insulin aspart 30: from drug development to the latest clinical findings.

Authors:  Andreas Liebl; Vinay Prusty; Paul Valensi; Ryuzo Kawamori; Jens Sandahl Christiansen; Andrew J Palmer; Per Balschmidt; Robert Ligthelm; Viswanathan Mohan
Journal:  Drugs       Date:  2012-07-30       Impact factor: 9.546

4.  Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia.

Authors:  Baptist Gallwitz; Michael Böhmer; Thomas Segiet; Andrea Mölle; Karsten Milek; Bernd Becker; Karin Helsberg; Helmut Petto; Natalie Peters; Oliver Bachmann
Journal:  Diabetes Care       Date:  2011-02-01       Impact factor: 19.112

5.  Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.

Authors:  Annachiara Uccellatore; Stefano Genovese; Ilaria Dicembrini; Edoardo Mannucci; Antonio Ceriello
Journal:  Diabetes Ther       Date:  2015-08-14       Impact factor: 2.945

6.  One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

Authors:  Mathijs C Bunck; Michaela Diamant; Anja Cornér; Bjorn Eliasson; Jaret L Malloy; Rimma M Shaginian; Wei Deng; David M Kendall; Marja-Riitta Taskinen; Ulf Smith; Hannele Yki-Järvinen; Robert J Heine
Journal:  Diabetes Care       Date:  2009-02-05       Impact factor: 17.152
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.